Each year almost 800,000 Americans have a heart attack. A heart attack happens when blood flow to the heart suddenly becomes blocked. Without the blood coming in, the heart can't get oxygen. If not treated quickly, the heart muscle begins to die. But if you do get quick treatment, you may be able to prevent or limit damage to the heart muscle. That's why it's important to know the symptoms of a heart attack and call 9-1-1 if you or someone else is having them. You should call, even if you are not sure that it is a heart attack.

The most common symptoms in men and women are

  • Chest discomfort. It is often in center or left side of the chest. It usually lasts more than a few minutes. It may go away and come back. It can feel like pressure, squeezing, fullness, or pain. It also can feel like heartburn or indigestion.
  • Shortness of breath. Sometimes this is your only symptom. You may get it before or during the chest discomfort. It can happen when you are resting or doing a little bit of physical activity.
  • Discomfort in the upper body. You may feel pain or discomfort in one or both arms, the back, shoulders, neck, jaw, or upper part of the stomach.

You may also have other symptoms, such as nausea, vomiting, dizziness, and lightheadedness. You may break out in a cold sweat. Sometimes women will have different symptoms then men. For example, they are more likely to feel tired for no reason.

The most common cause of heart attacks is coronary artery disease (CAD). With CAD, there is a buildup of cholesterol and other material, called plaque, on their inner walls or the arteries. This is atherosclerosis. It can build up for years. Eventually an area of plaque can rupture (break open). A blood clot can form around the plaque and block the artery.

A less common cause of heart attack is a severe spasm (tightening) of a coronary artery. The spasm cuts off blood flow through the artery.

At the hospital, health care providers make a diagnosis based on your symptoms, blood tests, and different heart health tests. Treatments may include medicines and medical procedures such as coronary angioplasty. After a heart attack, cardiac rehabilitation and lifestyle changes can help you recover.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for MYOCARDIAL INFARCTION

MYOCARDIAL INFARCTION treatment research studies

Celebrex clinical trials, surveys and public health registries

Find Drug Side Effect reports

Celebrex Side Effects

Myocardial Infarction (3006)
Cerebrovascular Accident (1828)
Pain (771)
Depression (580)
Hypertension (528)
Dyspnoea (510)
Arthralgia (500)
Cardiovascular Disorder (487)
Chest Pain (481)
Cardiac Disorder (412)
Rash (405)
Dizziness (396)
Cardiac Failure Congestive (366)
Pruritus (361)
Nausea (355)
Arthritis (354)
Anxiety (343)
Pain In Extremity (340)
Headache (340)
Fall (339)
Diarrhoea (283)
Condition Aggravated (282)
Malaise (274)
Thrombosis (270)
Asthenia (268)
Abdominal Pain Upper (266)
Transient Ischaemic Attack (262)
Oedema Peripheral (262)
Blood Cholesterol Increased (253)
Back Pain (244)
Feeling Abnormal (240)
Fatigue (229)
Blood Pressure Increased (222)
Dyspepsia (217)
Pulmonary Embolism (216)
Hypersensitivity (213)
Deep Vein Thrombosis (199)
Insomnia (193)
Abdominal Discomfort (186)
Coronary Artery Disease (185)
Acute Myocardial Infarction (182)
Atrial Fibrillation (178)
Arthropathy (177)
Weight Decreased (168)
Amnesia (165)
Vomiting (164)
Urticaria (158)
Gastrointestinal Haemorrhage (156)
Coronary Artery Occlusion (155)
Abdominal Pain (155)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

MYOCARDIAL INFARCTION Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting The Impact of Genotype on Plasma and Cerebral Spinal Fluid Pharmacokinetics of Celecoxib in Children
Condition: Pharmacokinetics of Celecoxib in Children
Intervention: Drug: Celecoxib
Outcome Measures: Change in Plasma and CSF concentrations of Celecoxib in children;   Genomic testing and interpretation of the CYP2C9 genotype;   Pediatric Quality of life Inventory;   Pediatric cancer module;   Multidimension Fatigue Inventory;   Pediatric Pain Inventory;   Demographics
2 Not yet recruiting Condrosulf vs Celebrex vs Placebo in the Treatment of Knee OA
Condition: Knee Osteoarthritis
Interventions: Drug: chondroitin sulfate;   Drug: celecoxib;   Drug: placebo
Outcome Measures: Lequesne's Index;   Pain (VAS in mm);   MCII (minimal clinically important improvement);   PASS (patient acceptable symptom state);   Consumption of Paracetamol;   Global efficacy assessment;   Number of adverse events related to the treatments;   Number of drop-outs due to AE (adverse event) related to the treatment
3 Not yet recruiting Intraviteral Celecoxib for Chronic Uveitis
Condition: Inflammation
Intervention: Drug: Intravitreal Celecoxib
Outcome Measures: Safety;   Efficacy
4 Recruiting Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: capecitabine;   Drug: celecoxib;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
Outcome Measures: AUC of celecoxib on combination therapy (day 14) and AUC of celecoxib on celecoxib monotherapy(day 7);   CYP2C9 genotype;   Response rate;   Drug-related toxicities;   PK drug interaction model
5 Not yet recruiting Safety of Fluvastatin-Celebrex Association in Low-grade Optico-chiasmatic Gliomas
Condition: Gliomas.
Interventions: Drug: Fluvastatine;   Drug: Celebrex
Outcome Measures: Maximum tolerated dose (MTD) of Fluvastatine combined to a fixed-dose of Celebrex;   Safety;   Efficacy;   Progression-free;   Potential interactions between the two drugs
6 Recruiting Delaying Ossification and Improving Inflammation of Celebrex Plus/or Enbrel Treatment on Active Ankylosing Spondylitis
Conditions: Inflammation;   Ankylosing Spondylitis
Interventions: Drug: Celebrex;   Drug: Enbrel;   Drug: Enbrel plus Celebrex
Outcome Measures: the SPARCC score of spine and SI joint;   mSASSS score of spine;   ASAS20 response rate;   ASAS20 response;   ASAS40 response;   ASAS70 response;   ASAS5/6 response
7 Recruiting Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component
Condition: Chronic Low Back Pain With a Neuropathic Component
Interventions: Drug: pregabalin and celecoxib;   Drug: Placebo and celecoxib
Outcome Measures: Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain).;   Benefit, Satisfaction, Willingness to Continue Measure (BSW);   Patient Global Impression of Change (PGI-C);   Daily Sleep Interference Rating Scale (SIRS);   Hospital Anxiety and Depression Scale (HADS);   Brief Pain Inventory-Short Form (BPI-sf) Score at Week X;   Sleep Disturbance Subscale in the Medical Outcome Study (MOS) Sleep Scale at Week X
8 Recruiting Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women
Condition: Obesity
Intervention: Drug: Celecoxib
Outcome Measure: To determine whether oral administration of Celebrex to obese women will reduce the PGE-M in urine
9 Recruiting Capecitabine and Celecoxib With or Without Radiation Therapy in Treating Patients With Colorectal Cancer Previously Treated With Fluorouracil
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: capecitabine;   Drug: celecoxib;   Radiation: radiation therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Radiation: intensity-modulated radiation therapy;   Radiation: stereotactic body radiation therapy
Outcome Measures: Rate of CR, assessed according to CEA and CA 19-9 measurements and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1;   Relapse free survival in patients achieving CR;   PFS as defined by true disease progression (new sites of disease);   Overall survival;   Best overall response rate, defined using RECIST 1.1;   K-ras mutation status;   Quality of life (QOL), assessed using the M.D. Anderson Symptom Inventory (MDASI);   Adverse events defined as any condition that appears or worsens after the subject is enrolled in an investigational study, graded by numerical score according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 4.0
10 Recruiting Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors
Condition: Breast Cancer
Interventions: Drug: Celecoxib;   Drug: Placebo;   Drug: Cholecalciferol
Outcome Measures: PG synthesis and metabolism;   Proliferative activity in the breast, as measured by MD cell morphology;   Circulating levels of 25(OH)D, 1,25(OH)2D, and celecoxib
11 Unknown  Effectiveness of Celecoxib After Surgical Sperm Retrieval
Condition: Pain
Interventions: Drug: Celecoxib;   Drug: Sugar Pill
Outcome Measures: Level of pain;   Bleeding complications
12 Unknown  A Trial Assessing the Outcome of Celecoxib Administration Versus Placebo Following Anterior Cruciate Ligament (ACL) Reconstruction
Condition: Pain
Interventions: Drug: Celecoxib;   Drug: Placebo
Outcome Measures: The primary outcome measure is to test the null hypothesis that Celecoxib perioperatively does not negatively influence the static testing of ACL reconstruction as measured by KT arthrometer at 2 years post op.;   The 2nd outcome tested by this study is that the celecoxib group experiences equal pain control compared with the placebo group.
13 Recruiting N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
Condition: Neuroblastoma
Interventions: Drug: DFMO;   Drug: Celecoxib;   Drug: Cyclophosphamide;   Drug: Topotecan
Outcome Measure: Number of participants with adverse events as a measure of safety and tolerability.
14 Recruiting Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)
Condition: Lung Cancer
Intervention: Drug: Celecoxib
Outcome Measures: overall survival;   progression-free survival
15 Unknown  Preemptive Analgesia Following Uterine Artery Embolization
Conditions: Uterine Fibroids;   Uterine Artery Embolization
Interventions: Drug: pregabalin/celecoxib;   Drug: pregabalin/placebo;   Drug: celecoxib/placebo;   Drug: Placebo group
Outcome Measures: post operative pain control;   Quality of life
16 Unknown  Arthroplasty Inflammation Prophylaxis With Celecoxib
Condition: Postoperative Pain
Intervention: Drug: Celecoxib
Outcome Measures: Compare total pain rating in group receiving 7day celecoxib against in 1 dose celecoxib;   1. Comparison of pain rating VRS "When you woke up following surgery," and at 24 hours and 48 hours postoperatively in the two study groups;   Comparison of patient reported maximum pain on VRS in the study groups.
17 Recruiting Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients
Conditions: Arthritis;   Cardiovascular Diseases;   Cerebrovascular Disorders
Interventions: Drug: Celecoxib(drug);   Drug: Naproxen(drug)
Outcome Measures: Recurrent ulcer bleeding within 78 weeks according to pre-specified criteria;   Cardiovascular events
18 Unknown  A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Taxotere;   Drug: Celecoxib
Outcome Measures: Determine the effect of Taxotere and celecoxib on PSA and objective response in patients with HRPC;   Evaluate the toxicity of the combination of celecoxib and Taxotere in patients with stage D3 prostate cancer.;   Determine the effects of this regimen on quality of life.;   Determine the survival of the patients treated
19 Recruiting Tramadol Versus Celecoxib for Reducing Pain in Outpatient Hysteroscopy
Condition: Pain
Interventions: Drug: Tramadol;   Drug: Celecoxib;   Drug: Placebo
Outcome Measures: Pain perception during the procedure;   Pain perception after the procedure
20 Unknown  Effect of Celecoxib on Transitional Pain After Outpatient Surgery
Condition: Pain
Interventions: Drug: Celebrex;   Drug: placebo
Outcome Measures: visual analogue score for pain;   severity of nausea